Watchlist Price Alert

Krystal Biotech Inc. (KRYS)

NASDAQ: KRYS · Real-Time Price · USD

141.12

4.32 (3.16%)

At close: May 08, 2025, 1:14 PM

3.16% (1D)

Bid	141.08
Market Cap	4.08B
Revenue (ttm)	290.51M
Net Income (ttm)	89.16M
EPS (ttm)	2.99
PE Ratio (ttm)	47.2
Forward PE	12.77
Analyst	Buy

Ask	141.54
Volume	231,386
Avg. Volume (20D)	319,339
Open	135.91
Previous Close	136.80
Day's Range	132.58 - 141.50
52-Week Range	132.47 - 219.34
Beta	0.78

About KRYS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol KRYS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for KRYS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Krystal Biotech has released their quartely earnings on May 6, 2025:

Revenue of $88.18M misses estimates by $8.03M, with 94.88% YoY growth.

EPS of 1.2 misses estimates by -0.32, with 160.87% YoY growth.

Why Price Moved

2 days ago

-14.06%

Krystal Biotech shares are trading lower after the... Unlock content with Pro Subscription

2 months ago

+3.66%

Krystal Biotech shares are trading higher after Chardan Capital raised its price target on the stock from $212 to $218.

News

2 days ago · seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma K...

2 days ago · zacks.com

Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down

KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.

1 day ago · zacks.com

Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.20 per share, missing the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $0.03 per share a year ago.

1 week ago · zacks.com

Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · zacks.com

5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

1 month ago · seekingalpha.com

Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK

Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuat...

1 month ago · zacks.com

Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

1 month ago · zacks.com

Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 months ago · zacks.com

Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?

KRYS stock surges 15% in a month on strong uptake of Vyjuvek and encouraging pipeline progress. We are optimistic about the stock as we believe there is room for further growth.

2 months ago · zacks.com

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.

Load More News